PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

Otsuka taps Shape in deal to design eye gene therapies

The companies will work together to pair Shape’s adeno-associated virus technology with Otsuka’s genetic payloads.

Japan’s Otsuka Pharmaceutical will work with Seattle startup Shape Therapeutics to develop gene therapies for the eye, announcing Thursday a research collaboration centered on Shape’s viral engineering technology.

With Shape’s help, Otsuka aims to develop adeno-associated virus-based gene therapies that can deliver into eye cells the genetic code for molecules and antibodies it’s identified to treat “chronic ocular diseases.”

Shape uses high throughput screening to parse a vast array of possible adeno-associated viruses, or AAVs, that could work as a delivery chassis for payloads like those Otsuka has in mind. It then applies machine learning to select the AAVs best targeted to specific tissues and less likely to stray from their cellular destination.

Francois Vigneault, Shape’s CEO and co-founder, compares how his company applies machine learning to generative AI tools like Midjourney and DALLE-2, which can create digital images from written descriptions.

“By incorporating diffusion models, our platform is designing novel medicines that transcend the boundaries of what is possible experimentally,” Vigneault said in a Sept. 7 statement.

Otsuka will pay Shape an undisclosed amount upfront and has promised more than $1.5 billion more if certain development, regulatory and sales milestones are met.

The partnership with Otsuka is Shape’s second with a large pharmaceutical company. Two years ago, on the heels of raising $112 million in Series B venture financing, the biotechnology firm struck a deal with Roche focused on applying RNA editing technology to neurological diseases.

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40